Patient Square Capital’s Yarrow Bioscience YARW Stock Holding History

Patient Square Capital’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,341	Closed	-$523K	–	27
2025 Q2	$523K	Buy	6,341 +1,200	+23%	+$78K	0.19%	19
2025 Q1	$406K	Buy	+5,141	New	+$633K	0.17%	19

Other funds holding YARW

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Patient Square Capital's YARW Position: Q3 2025 in Review

Patient Square Capital sold out of Yarrow Bioscience (YARW) in Q3 2025, closing a stake of 6,341 shares — an estimated $523K sold.

Patient Square Capital first reported a position in YARW in Q1 2025 and held it in 2 quarters. The position peaked at $523K in Q2 2025. 34 funds tracked by Wall St. Rank hold YARW as of Q3 2025.

Patient Square Capital reported no remaining Yarrow Bioscience position as of Q3 2025 after selling out during the quarter.
Patient Square Capital sold 6,341 Yarrow Bioscience shares in Q3 2025, an estimated $523K.
Patient Square Capital first reported a position in Yarrow Bioscience in Q1 2025 and held it in 2 quarters.
Patient Square Capital's Yarrow Bioscience position peaked at $523K in Q2 2025.
34 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2025.

Based on Patient Square Capital's 13F filing for Q3 2025, filed 10 Nov 2025.